ALAMEDA, Calif.--(BUSINESS WIRE)--Mar. 5, 2012-- InSite Vision Incorporated (OTCBB:INSV), a company developing ophthalmic products for unmet eye care needs, today announced that the company’s Annual Meeting of Stockholders will be held at 10:00 a.m. Pacific Time on Thursday, May 31, 2012, for shareholders of record on April 6, 2012. The Annual Meeting will be held at InSite Vision’s headquarters at 965 Atlantic Avenue, Alameda, California. InSite Vision plans to mail the definitive proxy statement for the Annual Meeting, as well as its annual report, in mid-April.

About InSite Vision

InSite Vision is advancing new and superior ophthalmologic products for unmet eye care needs. The company’s product portfolio utilizes InSite Vision’s proven DuraSite^® bioadhesive polymer core technology, an innovative platform that extends the duration of drug retention on the surface of the eye, thereby reducing frequency of treatment and improving the efficacy of topically delivered drugs. The DuraSite platform is currently leveraged in two commercial products for the treatment of bacterial eye infections, AzaSite^® (azithromycin ophthalmic solution) 1%, marketed in the U.S. by Merck, and Besivance^® (besifloxacin ophthalmic suspension) 0.6%, marketed globally by Bausch + Lomb. InSite Vision’s clinical-stage ophthalmic product pipeline includes AzaSite Plus^™ and DexaSite^™ for the treatment of eye infections, BromSite™ (ISV-303) for pain and swelling associated with ocular surgery, and ISV-101 for the treatment of dry eye disease. For further information on InSite Vision, please visit www.insitevision.com.

AzaSite^® and DuraSite^® are registered trademarks of InSite Vision Incorporated.

BESIVANCE^® is a registered trademark of Bausch + Lomb Incorporated.

Source: InSite Vision Incorporated

InSite Vision
Louis Drapeau, 510-747-1220
Chief Financial Officer
mail@insite.com
or
Media/Investor Inquiries
BCC Partners
Michelle Corral, 415-794-8662